• Corpus ID: 9479564

GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.

@article{Jones2009GSKsNS,
  title={GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.},
  author={Taff Jones},
  journal={Current opinion in molecular therapeutics},
  year={2009},
  volume={11 3},
  pages={
          337-45
        }
}
  • T. Jones
  • Published 1 June 2009
  • Biology
  • Current opinion in molecular therapeutics
Although influenza pandemics occur infrequently, they are unpredictable. Given that humans had not been previously exposed to the novel H5N1 strain, few (if any) individuals have any degree of immunity to the strain. GlaxoSmithKline plc (GSK) has developed two inactivated split H5N1 vaccines adjuvanted with GSK's proprietary oil-in-water emulsion AS03: GSK-1562902A (produced in Dresden, Germany) and GSK-1557484A (produced in Québec, Canada). The vaccines principally use an A/Vietnam strain… 

Antibody Response After a Single Dose of an AS03-Adjuvanted Split-Virion Influenza A (H1N1) Vaccine in Heart Transplant Recipients

Single-dose administration of an AS03-adjuvanted vaccine against the novel influenza A (H1N1) virus did not elicit seroprotective antibody concentrations in a substantial proportion of heart transplant recipients; the new pandemic influenza A IgG ELISA test kit proved to be of limited clinical use.

Influenza vaccine immunology

Studying the spread of influenza in human populations and protection by influenza vaccines provides important insights into immunity against influenza, and comparisons between non‐adjuvanted inactivated vaccines and live attenuated vaccines demonstrate that both can protect.

CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets

The data obtained in this human-relevant challenge model supports the potential of CAF01 in future influenza vaccines and improves the immunogenicity of the vaccine, with increased influenza-specific IgA and IgG levels.

Inferring Reasons for the Failure of Staphylococcus aureus Vaccines in Clinical Trials

Vaccines tested in humans to date were probably disproportionate to the complex pathogenic mechanisms of the bacterium and did not contain new generation adjuvants, which may be critical in augmenting antibody production and steering the T-cell response toward the proper profile of cytokine production.

An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines

Micro- and nanoparticulated vaccine delivery systems used in the field of synthetic peptide-based vaccines as well as strategies to increase their immunogenicity are summarized.

Active Immunization with Extracellular Vesicles Derived from Staphylococcus aureus Effectively Protects against Staphylococcal Lung Infections, Mainly via Th1 Cell-Mediated Immunity

It is shown that active immunization (vaccination) with S. aureus-derived EVs induce adaptive immunity of antibody and T cell responses, and that these EVs have the vaccine adjuvant ability to induce protective immunity.

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

Overall, emulsion adjuvants have demonstrated potent adjuvant activity across a number of disease indications along with acceptable safety profiles and indicate promising avenues for future emulsion-based adjUvant development.

Immunomodulators as adjuvants for vaccines and antimicrobial therapy

A highly effective strategy for combating infectious diseases is to enhance host defenses using immunomodulators, either preventatively, through vaccination, or therapeutically. The effectiveness of